CORDIS
EU research results

CORDIS

English EN
In Vivo Spectral Photon Counting CT Molecular Imaging in Cardio- and Neuro-Vascular Diseases

In Vivo Spectral Photon Counting CT Molecular Imaging in Cardio- and Neuro-Vascular Diseases

Objective

The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detect, characterize and monitor neurovascular and cardiovascular disease. Spectral Photon Counting Computed Tomography (SPCCT) is a new imaging modality, currently in development, with a totally new type of detection chain designed to provide high count-rate capabilities while offering energy discrimination with high spatial resolution of 200µm. Based on this discrimination, SPCCT can detect and quantify accurately a large variety of atoms (including Gadolinium, Gold, Bismuth…) by using the K-edge technique. SPCCT, by a more accurate, less invasive (in comparison with IVUS and coronary angiography) and reliable evaluation of vascular inflammation will allow earlier disease diagnosis such as plaque inflammation before rupture, leading to improved clinical decisions and outcomes. This will be achievable with a high spatial resolution combined to the newly developed vascular inflammation specific contrast agent detected with high quality K-edge technique that can only be provided by a multi-spectral X-ray system. The project will therefore provide a complete tool (acquisition system and specific probes) dedicated to CV imaging. It will finally contribute to: Improved early diagnosis of atherosclerosis, prevention of acute event (MI, stroke) and personalized preventive treatment; Improved management of patient presenting with an acute CV event and clinical validation of treatment efficiency; Sustainability and harmonization of healthcare systems, as costly disorders of heart failure and stroke-related disability would be better prevented and efficiently treated; Economic growth in the EU diagnostics sector, through the development of new targeted contrast materials for SPCCT by SMEs.

Coordinator

UNIVERSITE LYON 1 CLAUDE BERNARD

Address

Boulevard Du 11 Novembre 1918 Num43
69622 Villeurbanne Cedex

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 897 010

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

Philips GmbH

Germany

EU Contribution

€ 442 375

PHILIPS MEDICAL SYSTEMS TECHNOLOGIES LTD

Israel

EU Contribution

€ 1 505 000

MATHYM

France

EU Contribution

€ 269 062,50

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 441 750

VOXCAN

France

EU Contribution

€ 392 201,25

ERASMUS UNIVERSITEIT ROTTERDAM

Netherlands

EU Contribution

€ 405 478,75

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

EU Contribution

€ 195 817,50

LYON INGENIERIE PROJETS

France

EU Contribution

€ 211 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 331 968,75

BRACCO IMAGING SPA

Italy

EU Contribution

€ 350 000

Project information

Grant agreement ID: 668142

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 441 663,75

  • EU contribution

    € 6 441 663,75

Coordinated by:

UNIVERSITE LYON 1 CLAUDE BERNARD

France